Upcoming Webinars

Missed a Session?

Catch up anytime — previous webinars in this series are available on our on-demand page.

View On-Demand Webinars

Special Edition RMSS Journal Club: RETNET Trial

Monday, 17 November 2025 | 6:30 - 7:30 p.m. ET

Explore findings from a landmark multicenter randomized trial comparing embolization strategies for liver-dominant neuroendocrine tumor metastases. This session will examine early clinical outcomes, challenges in conducting multicenter prospective trials, and implications for clinical practice. Attendees will gain insights into trial design, safety monitoring, and how emerging data may shape future research and guideline recommendations in liver-directed therapies.

Faculty

Kirema Garcia-Reyes

Gavin Yuang, MD

Virginia Mason Franciscan Health

Riad Salem, MD

Michael Soulen, MD, FSIR, FCIRSE

University of Pennsylvania

Register Now

This webinar is sponsored by:

AstraZeneca
 

Evidence to Impact Roundtable: Treating Large HCC Tumors with TheraSphere™ Y-90 Glass Microspheres

Join this expert-led discussion on how TheraSphere™ Y-90 is redefining treatment for large hepatocellular carcinoma (HCC) tumors. The roundtable discussion will highlight real-world case examples that offer insights into how high-dose, high-RPM therapy is delivering results where it matters most.

Wednesday, 10 December 2025 | 7 – 8 p.m. ET

Faculty

Moderator

headshot

Christopher Malone, MD 

Washington University, St. Louis 

Faculty Panel

Anuj Malhotra, MD, FSIR, RPVI

NYU Grossman

Jeffrey Critchfield, MD, FSIR

Karmanos Cancer Center

Register Now

This webinar is sponsored by:

Boston Scientific

 


 

Targeting Tumors from Within: Intratumoral Therapies and Team-Based Care in Metastatic Melanoma

Postponed: Stay tuned for more details 

Join us for an engaging webinar titled “Targeting Tumors from Within: Intratumoral Therapies and Team-Based Care in Metastatic Melanoma,” sponsored by Replimune and Johnson & Johnson. This session will explore the evolving treatment landscape for advanced melanoma, with a particular focus on patients who have progressed on PD-1 inhibitors. Attendees will gain valuable insights into second-line treatment strategies, including the role of oncolytic immunotherapies. 

Faculty

Rahul Sheth, MD, FSIR

Rahul Sheth, MD, FSIR

MD Anderson Cancer Center

Michael Wong, MD, PhD, FRCPC

Michael Wong, MD, PhD, FRCPC

Roswell Park Comprehensive Cancer Center

This webinar is sponsored by:

AstraZeneca Varian